Allergy Therapeutics (AGY) Shares Down 36.8%

Allergy Therapeutics plc (LON:AGY)’s share price dropped 36.8% during trading on Monday . The company traded as low as GBX 9.10 ($0.12) and last traded at GBX 9.10 ($0.12). Approximately 745,785 shares traded hands during mid-day trading, an increase of 345% from the average daily volume of 167,682 shares. The stock had previously closed at GBX 14.40 ($0.19).

AGY has been the topic of a number of recent analyst reports. Numis Securities reiterated a “buy” rating and issued a GBX 45 ($0.59) price objective on shares of Allergy Therapeutics in a report on Wednesday, March 6th. FinnCap restated a “corporate” rating on shares of Allergy Therapeutics in a research note on Wednesday, March 6th.

The company has a market cap of $53.12 million and a PE ratio of -16.70. The company has a debt-to-equity ratio of 6.20, a quick ratio of 3.08 and a current ratio of 3.74.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2019/03/20/allergy-therapeutics-agy-shares-down-36-8.html.

About Allergy Therapeutics (LON:AGY)

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.

Further Reading: Terms to Better Understand Call Options

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.